Philipp Bloching M.D.

Philipp Bloching MD has a diverse work experience spanning from 2010 to present. Philipp started their career with an internship at Bank of America Merrill Lynch's Global Loans and Special Situations Group, where they conducted analysis of investment objectives and valuations of target companies. In 2013, they joined Novartis as a Trainee, where they worked on various projects related to global pricing and market access.

In 2014, Philipp Bloching MD was promoted to a Junior Market Access Manager at Novartis. Philipp then moved on to become a Market Access Manager and later a Brand Manager in the MS/Neuroscience department. During their time at Novartis, they gained experience in strategic planning, market access, and marketing.

In 2017, Philipp Bloching MD joined the Healthcare Business of Merck, where they held several roles including Head of Business Relationship Management Neurology (Sales) and Country Medical Director. In these positions, they led sales teams, focused on strategic collaboration with top accounts, and was responsible for medical education for healthcare professionals and nurses.

Currently, Philipp Bloching MD is the Chief Executive Officer and Managing Director at Desitin Arzneimittel GmbH, a position they have held since 2020. In this role, they are responsible for co-leading the company, overseeing its sales and pre-tax profit.

Overall, Philipp Bloching MD has a strong background in the pharmaceutical industry, with expertise in sales, market access, strategic planning, and medical education.

Philipp Bloching MD received their Doctor of Medicine (Dr. med. univ.) and license to practice medicine from the Medical University of Vienna, where they studied from 2005 to 2012. During this time, they also pursued a Bachelor of Science (B.Sc.) in Business, Economics, and Social Sciences at WU (Vienna University of Economics and Business), completing their degree in 2012. In 2018, they undertook advanced studies in the European Center of Pharmaceutical Medicine at the University of Basel from 2018 to 2020.